Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Classifica tra le azioni #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Prezzo delle azioni
$0.11725176
Ultima sincronizzazione: 2025-07-14
Capitalizzazione di mercato
$481.50K
Variazione (1 giorno)
-0.20%
Variazione (1 anno)
0.00%
Paese
FR
Scambia PHAXIAM Therapeutics S.A. (PHXM)

Categoria

Healthcare
Rapporto P/S per PHAXIAM Therapeutics S.A. (PHXM)
Rapporto P/S al August 2026 TTM: 0.76
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di PHAXIAM Therapeutics S.A., il rapporto P/S attuale (TTM) è 0.76. Alla fine del 2022, era pari a 1.71.
Storico del rapporto P/S per PHAXIAM Therapeutics S.A. da 2016 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
2026 (TTM) 0.76 -94.94%
2023 15.05 779.26%
2022 1.71 -85.75%
2021 12.01 -65.83%
2020 35.16 54.56%
2019 22.75 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.88 1,197.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.30 1,252.63%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
4.98 553.71%
BE